Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells
Yasuto Akiyama(Shizuoka Cancer Center), Ken Yamaguchi(National Cancer Center), Yukie Hotate(National Cancer Centre Japan), Naoki Inoue(Mukogawa Women's University), Ikuei Nukaya(Biota Pharmaceuticals (United States)), Kouji Maruyama(Shizuoka Cancer Center), Yoichi Takaue(National Cancer Center), Akifumi Yamamoto(Saitama Medical University), Makiko Shimada(National Cancer Centre Japan), Ichiro Kawashima(University of Yamanashi Hospital), Naoya Yamazaki(Tokyo National Hospital), Ryuji Tanosaki(National Cancer Center), Kazutoh Takesako(Biota Pharmaceuticals (United States))
Cited by 48
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
|Cancer Cell|2022|828